Strides Pharma Science Ltd's Q4FY25 Quarter Results
- 23 May 2025
Result Summary
- Strides Pharma Science Ltd reported a 7.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 5.6%.
- Its expenses for the quarter were down by 5.7% QoQ and up 1.2% YoY.
- The net profit decreased 88.4% QoQ and decreased 175.8% YoY.
- The earnings per share (EPS) of Strides Pharma Science Ltd stood at 2 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1070.49 | 1159.28 | 1013.49 | -7.7% | 5.6% |
Total Expenses | 984.22 | 1043.96 | 972.26 | -5.7% | 1.2% |
Profit Before Tax | 78.20 | 112.89 | 33.89 | -30.7% | 130.7% |
Tax | 19.25 | 23.80 | 7.09 | -19.1% | 171.5% |
Profit After Tax | 10.45 | 90.04 | -13.79 | -88.4% | -175.8% |
Earnings Per Share | 2.00 | 9.60 | -1.10 | -79.2% | -281.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Strides Pharma Science Ltd is a pharmaceutical company engaged in the development, manufacture, and marketing of a wide range of pharmaceutical products. The company operates in the pharmaceutical industry, focusing on generic drugs, which are alternatives to branded medications. Strides Pharma Science Ltd has a diverse portfolio that includes both prescription and over-the-counter medications, catering to various therapeutic segments. As of the latest updates available, no specific recent developments have been reported. However, the company is known for its global presence and engagements in regulated markets, which is a significant aspect of its business operations.
Revenue
For the fourth quarter of fiscal year 2025 (Q4FY25), Strides Pharma Science Ltd reported a total income of ₹1070.49 crores. This represents a decrease of 7.7% compared to the preceding quarter (Q3FY25), where total income was ₹1159.28 crores. However, when compared to the same quarter in the previous fiscal year (Q4FY24), where the total income was ₹1013.49 crores, there is an increase of 5.6% year-over-year (YoY). The fluctuation in revenue indicates variations in the company's earning capacity over the different periods, with a notable decrease in the latest quarter compared to the previous one.
Profitability
Strides Pharma Science Ltd's profitability metrics for Q4FY25 show a profit before tax (PBT) of ₹78.20 crores, which is a 30.7% decline from the previous quarter (Q3FY25) where the PBT was ₹112.89 crores. Year-over-year, there is a significant increase of 130.7% compared to Q4FY24’s PBT of ₹33.89 crores. The tax expense for Q4FY25 was ₹19.25 crores, reflecting a 19.1% decrease from Q3FY25 and a substantial 171.5% increase from Q4FY24. The profit after tax (PAT) for Q4FY25 stands at ₹10.45 crores, which is an 88.4% decline from Q3FY25’s ₹90.04 crores but a marked improvement from the loss of ₹13.79 crores in Q4FY24. These figures illustrate changes in profitability over the quarters and year, with significant variances observed.
Operating Metrics
The earnings per share (EPS) for Strides Pharma Science Ltd in Q4FY25 was ₹2.00, which decreased by 79.2% from Q3FY25’s EPS of ₹9.60. Compared to Q4FY24, where the EPS was negative at -₹1.10, there is a notable improvement. Total expenses for the quarter were ₹984.22 crores, showing a 5.7% reduction from the previous quarter’s expenses of ₹1043.96 crores and a slight increase of 1.2% from Q4FY24’s expenses of ₹972.26 crores. The operating metrics highlight the company's cost management and earnings relative to shareholder value, with visible fluctuations in expenses and earnings per share across the compared periods.